Filing Details
- Accession Number:
- 0001213900-20-006030
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-11 17:12:05
- Reporting Period:
- 2020-03-09
- Accepted Time:
- 2020-03-11 17:12:05
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1658247 | Crinetics Pharmaceuticals Inc. | CRNX | () | 1231 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1618788 | Vivo Capital Fund Viii, L.p. | C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto CA 94301 | No | No | Yes | No | |
1618789 | Vivo Capital Viii, Llc | C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto CA 94301 | No | No | Yes | No | |
1628048 | Vivo Capital Surplus Fund Viii, L.p. | C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto CA 94301 | No | No | Yes | No | |
1726403 | Vivo Opportunity Fund, L.p. | C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto CA 94301 | No | No | Yes | No | |
1728970 | Vivo Opportunity, Llc | C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto CA 94301 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-03-09 | 347 | $19.50 | 2,722,045 | No | 4 | S | Indirect | See Footnote |
Common Stock | Disposition | 2020-03-09 | 48 | $19.50 | 375,880 | No | 4 | S | Indirect | See Footnote |
Common Stock | Disposition | 2020-03-09 | 133 | $19.50 | 168,165 | No | 4 | S | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Indirect | See Footnote |
Footnotes
- These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").
- These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").
- These securities are held of record by Vivo Opportunity Fund, L.P. ("VOF").
- Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.
- Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.
- The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.3 to $19.7, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.